T cell-engaging therapies—BiTEs and beyond
ME Goebeler, RC Bargou - Nature Reviews Clinical Oncology, 2020 - nature.com
Immuno-oncology approaches have entered clinical practice, with tremendous progress
particularly in the field of T cell-engaging therapies over the past decade. Herein, we provide …
particularly in the field of T cell-engaging therapies over the past decade. Herein, we provide …
[HTML][HTML] Overall survival benefit with tebentafusp in metastatic uveal melanoma
P Nathan, JC Hassel, P Rutkowski… - … England Journal of …, 2021 - Mass Medical Soc
Background Uveal melanoma is a disease that is distinct from cutaneous melanoma, with a
low tumor mutational burden and a 1-year overall survival of approximately 50% in patients …
low tumor mutational burden and a 1-year overall survival of approximately 50% in patients …
Targeting a neoantigen derived from a common TP53 mutation
EHC Hsiue, KM Wright, J Douglass, MS Hwang… - Science, 2021 - science.org
INTRODUCTION TP53 (tumor protein P53), a tumor suppressor gene, is the most commonly
mutated cancer-driver gene. Nevertheless, drugs that target mutant p53, the protein product …
mutated cancer-driver gene. Nevertheless, drugs that target mutant p53, the protein product …
Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial
In patients with previously treated metastatic uveal melanoma, the historical 1 year overall
survival rate is 37% with a median overall survival of 7.8 months. We conducted a …
survival rate is 37% with a median overall survival of 7.8 months. We conducted a …
T-cell-engaging bispecific antibodies in cancer
NWCJ van de Donk, S Zweegman - The Lancet, 2023 - thelancet.com
T-cell-engaging bispecific antibodies (BsAbs) simultaneously bind to antigens on tumour
cells and CD3 subunits on T cells. This simultaneous binding results in the recruitment of T …
cells and CD3 subunits on T cells. This simultaneous binding results in the recruitment of T …
Bispecific antibodies: a mechanistic review of the pipeline
AF Labrijn, ML Janmaat, JM Reichert… - Nature reviews Drug …, 2019 - nature.com
The term bispecific antibody (bsAb) is used to describe a large family of molecules designed
to recognize two different epitopes or antigens. BsAbs come in many formats, ranging from …
to recognize two different epitopes or antigens. BsAbs come in many formats, ranging from …
T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome
CA Klebanoff, SS Chandran, BM Baker… - Nature Reviews Drug …, 2023 - nature.com
The T cell receptor (TCR) complex is a naturally occurring antigen sensor that detects,
amplifies and coordinates cellular immune responses to epitopes derived from cell surface …
amplifies and coordinates cellular immune responses to epitopes derived from cell surface …
HLA variation and disease
Fifty years since the first description of an association between HLA and human disease,
HLA molecules have proven to be central to physiology, protective immunity and …
HLA molecules have proven to be central to physiology, protective immunity and …
Tebentafusp, a TCR/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma
MR Middleton, C McAlpine, VK Woodcock… - Clinical Cancer …, 2020 - AACR
Purpose: Tebentafusp is a first-in-class bispecific fusion protein designed to target gp100 (a
melanoma-associated antigen) through a high affinity T-cell receptor (TCR) binding domain …
melanoma-associated antigen) through a high affinity T-cell receptor (TCR) binding domain …